



AHCL/ SE/38/2025-26

February 3, 2026

<b>The National Stock Exchange of India Limited</b> "Exchange Plaza", C-1, Block G Bandra-Kurla Complex, Bandra (E) Mumbai 400 051 ISIN: INE098F01031 <b>Symbol: AMRUTANJAN</b>	<b>BSE Limited</b> Department of Corporate Services 1 <sup>st</sup> Floor, P.J. Towers, Dalal Street, Mumbai 400 001 ISIN: INE098F01031 <b>Scrip Code: 590006</b>
--	--

Dear Sir / Madam,

**Sub: Outcome of the Board Meeting**

In terms of Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR), we wish to inform that the Board of Directors of the Company at its meeting held today **February 3, 2026** has inter-alia:

- (i) Approved the Unaudited Financial Results for the quarter and Nine Months ended December 31, 2025, as recommended by the Audit Committee at its meeting held on February 3, 2026. The same along with the Unmodified Limited Review Report issued by M/s. B S R & Co. LLP, Statutory Auditors of the Company is enclosed.
- (ii) Declared Second Interim Dividend of Re.1/- per share for the financial year 2025-26 on the Equity Shares of the Company.
- (iii) The Company took note of the ESG rating of 68.6 (Environment -51.9/Social- 63.9/Governance- 82) by SES ESG Research Private Limited (registered with SEBI as an ESG rating provider under Category II—IN/ERP/Category-II/0002). This rating reflects the company's performance on Environmental, Social and Governance parameters as assessed by the rating agency.

The link for the rating as published by SES ESG Research Private Limited is [https://www.sesesg.com/all-esg-reports?com\\_name=AMRUTANJAN](https://www.sesesg.com/all-esg-reports?com_name=AMRUTANJAN)

Please note that the company has not engaged SES ESG Research Private Limited for ESG rating. SES ESG Research Private Limited has independently prepared the report based on the data available in public domain.

The communication is also made available on the website of the company.

The Board Meeting commenced at 12:45 P.M and concluded at 5.00 P.M. Request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For **Amrutanjan Health Care Limited**

**(Gagan Preet Singh)**  
**General Manager- Legal**  
**Company Secretary-cum-Compliance Officer**

**Encl:**

1. Un-audited Standalone Financials Results for the quarter and Nine Months ended December 31, 2025
2. Limited Review Report

**Statement of Unaudited Financial Results for the quarter and nine months ended 31 December 2025**

		Quarter ended			Period ended		(Amount in INR Lakhs)
	Particulars	31 December 2025	30 September 2025	31 December 2024	31 December 2025	31 December 2024	Year ended
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	31 March 2025
I	Revenue from operations	14,103.87	11,770.02	12,275.15	35,278.46	31,640.27	45,181.63
II	Other income	411.96	429.63	436.03	1,284.33	1,285.94	1,767.87
III	<b>Total income (I + II)</b>	<b>14,515.83</b>	<b>12,199.65</b>	<b>12,711.18</b>	<b>36,562.79</b>	<b>32,926.21</b>	<b>46,949.50</b>
IV	<b>Expenses</b>						
	(a) Cost of materials consumed	2,876.68	2,512.38	2,597.92	7,512.69	6,564.72	10,059.69
	(b) Purchase of stock-in-trade	3,329.31	3,519.07	3,045.56	9,964.65	9,224.86	12,317.94
	(c) Changes in inventories of finished goods, work-in progress and stock-in-trade	173.36	(265.95)	(63.56)	(393.47)	(368.23)	(56.90)
	(d) Employee benefits expense	1,614.93	1,595.08	1,470.27	4,811.32	4,308.54	5,910.27
	(e) Finance cost	4.79	4.97	5.59	14.91	17.59	21.92
	(f) Depreciation and amortisation expense	162.44	155.77	166.39	471.28	490.39	652.61
	(g) Other expenses						
	- Advertisement and selling expenditure	2,133.96	1,374.95	1,656.16	4,245.85	4,023.31	5,611.04
	- Others	1,458.79	1,381.89	1,233.93	4,123.23	3,837.20	5,519.53
	<b>Total expenses (IV)</b>	<b>11,754.26</b>	<b>10,278.16</b>	<b>10,112.26</b>	<b>30,750.46</b>	<b>28,098.38</b>	<b>40,036.10</b>
V	<b>Profit before exceptional item and tax (III - IV)</b>	<b>2,761.57</b>	<b>1,921.49</b>	<b>2,598.92</b>	<b>5,812.33</b>	<b>4,827.83</b>	<b>6,913.40</b>
VI	<b>Exceptional Item</b>						
	Impact of New labour codes (refer Note 7)	125.17	-	-	125.17	-	-
VII	<b>Profit before tax (V - VI)</b>	<b>2,636.40</b>	<b>1,921.49</b>	<b>2,598.92</b>	<b>5,687.16</b>	<b>4,827.83</b>	<b>6,913.40</b>
VIII	<b>Tax expenses</b>	<b>691.18</b>	<b>525.33</b>	<b>674.35</b>	<b>1,514.66</b>	<b>1,262.14</b>	<b>1,829.93</b>
IX	<b>Profit after tax (VII - VIII)</b>	<b>1,945.22</b>	<b>1,396.16</b>	<b>1,924.57</b>	<b>4,172.50</b>	<b>3,565.69</b>	<b>5,083.47</b>
X	<b>Other comprehensive income / (loss)</b>						
	Items that will not be reclassified subsequently to profit or loss						
	Re-measurement gain/(loss) on defined benefit plans	0.15	(26.08)	(56.57)	(33.45)	(100.41)	(105.87)
	Income tax relating to items that will not be reclassified to profit or loss	(0.04)	6.57	14.24	8.42	25.27	26.65
	<b>Other comprehensive income/ (loss), net of taxes</b>	<b>0.11</b>	<b>(19.51)</b>	<b>(42.33)</b>	<b>(25.03)</b>	<b>(75.14)</b>	<b>(79.22)</b>
XI	<b>Total comprehensive income (IX + X)</b>	<b>1,945.33</b>	<b>1,376.65</b>	<b>1,882.24</b>	<b>4,147.47</b>	<b>3,490.55</b>	<b>5,004.25</b>
	Equity share capital (Face value INR 1/- each, fully paid up)	289.11	289.11	289.11	289.11	289.11	289.11
	Other equity						32,372.35
	<b>Earnings per equity share</b>						
	Basic earnings per share (INR)	6.73	4.83	6.66	14.43	12.33	17.58
	Diluted earnings per share (INR)	6.73	4.83	6.66	14.43	12.33	17.58
	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)

See accompanying notes to Unaudited financial results



**AMRUTANJAN HEALTH CARE LIMITED**  
**CIN No : L24231TN1936PLC000017**  
Registered Office: No. 103 (Old No. 42-45), Luz Church Road  
Mylapore, Chennai - 600 004

**Notes:**

- The above unaudited financial results for the quarter and nine months ended 31 December 2025 in respect of Amrutanjan Health Care Limited ('the Company') have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on 03 February 2026. The above unaudited financial results have been subjected to limited review by the statutory auditors of the Company. The auditors have issued an unmodified review report.
- These unaudited financial results have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The Company does not have any subsidiary/associate/joint venture company(ies) and hence there is no requirement to prepare Consolidated Financial Results.
- Interim Dividend of INR 1/- per share, aggregating to INR 289.11 Lakhs has been paid during the quarter ended 31 December 2025.
- During the financial year 2020-2021, Amrutanjan's Board of Directors had approved the Amrutanjan Health Care Limited Employee stock option scheme ('Scheme 2020') for the grant of stock options to the employees of the Company. The Compensation Committee administers the plan through a trust established specifically for this purpose, called Amrutanjan Health Care Limited ESOP trust ('ESOP trust'). The assets and liabilities of the trust is accounted for as assets and liabilities of the Company on the basis that the trust is exclusively set up for the purpose of administering the ESOP plan of the Company. Further, based on the recommendation of the Compensation Committee, the Board of Directors of the Company has approved further grants under the scheme mentioned above, at its meeting held on 23 May 2024.
- During the financial year 2005-06, the Government of Tamil Nadu retrospectively revised the lease rent for a leasehold land, effective from November 2001, by determining fair rent under Section 34A of the Tamil Nadu Hindu Religious and Charitable Endowments Act, 1959. Pursuant to this revision, a demand notice was issued to the Company. Accordingly, the Company had filed a Writ Petition before the High Court of Judicature, Madras challenging the fair rent determination, contending that the revision was exorbitant and not legally tenable. On 25 September 2025, the High Court of Judicature, Madras has dismissed the petition and upheld the rent fixed by the Fair Rent Committee constituted by the Government of Tamil Nadu. Based on the advice from the external consultant, the Company has filed an appeal on 9th December 2025 before the Division Bench of the High Court of Judicature, Madras and hence no adjustments have been considered in the unaudited financial results.
- On November 21, 2025, the Government of India notified four Labour codes - the Code on Wages, 2019, the Code on Social Security, 2020, the Industrial Relations Code, 2020 and the Occupational safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and disclosed for the incremental impact of these changes on the basis of best information available, consistent with the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company has presented such incremental impact as "Impact of new Labour Codes" under "Exceptional items" in the unaudited financial results for the quarter and nine months ended 31st December 2025. The incremental impact consisting of gratuity and leave encashment benefits of INR 125.17 lakhs, primarily arising due to change in wage definition. The Company continues to monitor the finalisation of Central/ State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.
- The unaudited financial results of the Company for the quarter and nine months ended 31 December 2025 have been filed with the National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) and are available in Company's website [www.amrutanjan.com](http://www.amrutanjan.com).
- Segment reporting in the Unaudited financial results:** Based on the 'management approach' as defined in Ind AS 108 'Operating Segments', the Chief Operating Decision Maker evaluates the Company's performance as OTC Products, Women's Hygiene, Beverages and Other segment (represents Pain Management Centre).

(Amount in INR Lakhs)

Particulars	Quarter ended			Period ended		
	31 December 2025 (Unaudited)	30 September 2025 (Unaudited)	31 December 2024 (Unaudited)	31 December 2025 (Unaudited)	31 December 2024 (Unaudited)	Year ended 31 March 2025 (Audited)
<b>1 Segment revenue</b>						
a OTC Products	10,054.02	8,001.84	8,793.34	23,753.10	20,724.65	29,002.99
b Women's Hygiene	3,667.97	3,278.04	2,992.59	9,806.76	8,950.70	12,396.25
c Beverages	309.40	428.84	441.67	1,514.25	1,876.04	3,643.01
d Others	72.48	61.30	47.55	204.35	88.88	139.38
<b>Total</b>	<b>14,103.87</b>	<b>11,770.02</b>	<b>12,275.15</b>	<b>35,278.46</b>	<b>31,640.27</b>	<b>45,181.63</b>
<b>2 Segment results</b>						
a OTC Products	2,752.54	1,841.04	2,396.20	5,672.72	4,531.16	6,557.17
b Women's Hygiene	(32.37)	(125.74)	(47.14)	(143.26)	(213.82)	(391.05)
c Beverages	(352.05)	(64.87)	(28.26)	(716.74)	(277.96)	(243.56)
d Others	(4.47)	(15.10)	(16.47)	(24.08)	(58.71)	(81.43)
<b>Total</b>	<b>2,363.65</b>	<b>1,635.33</b>	<b>2,304.33</b>	<b>4,788.64</b>	<b>3,980.67</b>	<b>5,841.13</b>
Less: Finance cost	4.79	4.97	5.59	14.91	17.59	21.92
Add: Interest income net of other unallocable expenditure	277.54	291.13	300.18	913.43	864.75	1,094.19
<b>Total profit before tax</b>	<b>2,636.40</b>	<b>1,921.49</b>	<b>2,598.92</b>	<b>5,687.16</b>	<b>4,827.83</b>	<b>6,913.40</b>
<b>3 Segment assets</b>						
a OTC Products	7,254.27	7,027.96	6,843.98	7,254.27	6,843.98	6,800.73
b Women's Hygiene	7,939.62	6,877.07	3,664.16	7,939.62	3,664.16	5,209.00
c Beverages	2,387.88	2,566.63	2,391.71	2,387.88	2,391.71	3,503.26
d Others	129.50	126.35	115.08	129.50	115.08	122.13
e Unallocated assets	27,412.37	26,637.81	26,277.31	27,412.37	26,277.31	26,503.68
<b>Total</b>	<b>45,123.64</b>	<b>43,235.82</b>	<b>39,292.24</b>	<b>45,123.64</b>	<b>39,292.24</b>	<b>42,138.80</b>
<b>4 Segment liabilities</b>						
a OTC Products	6,034.67	5,190.02	5,453.53	6,034.67	5,453.53	5,539.80
b Women's Hygiene	1,418.48	1,673.34	1,215.97	1,418.48	1,215.97	1,646.36
c Beverages	794.98	690.98	508.28	794.98	508.28	1,359.50
d Others	42.98	65.64	40.01	42.98	40.01	42.67
e Unallocated liabilities	925.26	1,409.07	665.32	925.26	665.32	889.01
<b>Total</b>	<b>9,216.37</b>	<b>9,029.05</b>	<b>7,883.11</b>	<b>9,216.37</b>	<b>7,883.11</b>	<b>9,477.34</b>
<b>Total capital employed in the Company</b>	<b>35,907.27</b>	<b>34,206.77</b>	<b>31,409.13</b>	<b>35,907.27</b>	<b>31,409.13</b>	<b>32,661.46</b>

For Amrutanjan Health Care Limited



S Sambhu Prasad  
Chairman & Managing Director  
DIN: 00015729

Date: 3 February 2026  
Place: Chennai



# B S R & Co. LLP

Chartered Accountants

KRM Tower, 1st and 2nd Floors  
No. 1, Harrington Road, Chetpet  
Chennai – 600 031, India  
Telephone: +91 44 4608 3100  
Fax: +91 44 4608 3199

## Limited Review Report on unaudited financial results of Amrutanjan Health Care Limited for the quarter ended 31 December 2025 and year to date results for the period from 1 April 2025 to 31 December 2025 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

### To the Board of Directors of Amrutanjan Health Care Limited

1. We have reviewed the accompanying Statement of unaudited financial results of **Amrutanjan Health Care Limited** (hereinafter referred to as "the Company") for the quarter ended 31 December 2025 and year to date results for the period from 1 April 2025 to 31 December 2025 ("the Statement") in which are included the unaudited financial results of Amrutanjan Health Care Limited ESOP Trust ("ESOP trust").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.: 101248W/W-100022

**R Kalyana Sundara Rajan**

Partner

Chennai

03 February 2026

Membership No.: 221822

UDIN: 26221822JBNGP4847

Registered Office

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063